Previous 10 | Next 10 |
home / stock / apls / apls articles
NEW ORLEANS, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charle...
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders...
LOS ANGELES, Sept. 06, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on...
LOS ANGELES, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming October 2, 2023 deadl...
NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Apellis Pharmaceuticals, Inc. ("Apellis" or...
NEW YORK, Sept. 02, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Lifshitz Law PLLC announces investigation into possibl...
NEW YORK, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds inves...
NEW YORK, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Apellis Pharmaceuticals, Inc. ("Ape...
NEW YORK, Aug. 31, 2023 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders ...
News, Short Squeeze, Breakout and More Instantly...
Apellis Pharmaceuticals Inc. Company Name:
APLS Stock Symbol:
NASDAQ Market:
Apellis Pharmaceuticals Inc. Website:
WALTHAM, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its second quarter 2024 financial results on Thursday, August 1, 2024, at 8:30 a.m. ET. To access ...
Late-breaking presentation shows SYFOVRE® (pegcetacoplan injection) demonstrated visual function benefit on prespecified endpoint in GALE long-term extension study WALTHAM, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that six ...
WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion on the marketing authorization application (MAA) of i...